Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma

Steven P. Rowe, Michael A. Gorin, Hans J. Hammers, Martin G. Pomper, Mohammad E. Allaf, Mehrbod Som Javadi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

Original languageEnglish (US)
Pages (from-to)83-85
Number of pages3
JournalClinical Nuclear Medicine
Volume41
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Fluorodeoxyglucose F18
Renal Cell Carcinoma
Neoplasms
Therapeutics
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid

Keywords

  • metastatic renal cell carcinoma
  • PET/CT
  • prostate-specific membrane antigen (PSMA)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. / Rowe, Steven P.; Gorin, Michael A.; Hammers, Hans J.; Pomper, Martin G.; Allaf, Mohammad E.; Javadi, Mehrbod Som.

In: Clinical Nuclear Medicine, Vol. 41, No. 1, 01.01.2016, p. 83-85.

Research output: Contribution to journalArticle

Rowe, Steven P. ; Gorin, Michael A. ; Hammers, Hans J. ; Pomper, Martin G. ; Allaf, Mohammad E. ; Javadi, Mehrbod Som. / Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. In: Clinical Nuclear Medicine. 2016 ; Vol. 41, No. 1. pp. 83-85.
@article{f47308bae00e4929bcfadd121c957e53,
title = "Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.",
keywords = "metastatic renal cell carcinoma, PET/CT, prostate-specific membrane antigen (PSMA)",
author = "Rowe, {Steven P.} and Gorin, {Michael A.} and Hammers, {Hans J.} and Pomper, {Martin G.} and Allaf, {Mohammad E.} and Javadi, {Mehrbod Som}",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/RLU.0000000000000995",
language = "English (US)",
volume = "41",
pages = "83--85",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma

AU - Rowe, Steven P.

AU - Gorin, Michael A.

AU - Hammers, Hans J.

AU - Pomper, Martin G.

AU - Allaf, Mohammad E.

AU - Javadi, Mehrbod Som

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

AB - Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

KW - metastatic renal cell carcinoma

KW - PET/CT

KW - prostate-specific membrane antigen (PSMA)

UR - http://www.scopus.com/inward/record.url?scp=84951907767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951907767&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000995

DO - 10.1097/RLU.0000000000000995

M3 - Article

C2 - 26402128

AN - SCOPUS:84951907767

VL - 41

SP - 83

EP - 85

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 1

ER -